Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia
Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved t...
Gespeichert in:
Veröffentlicht in: | Schizophrenia bulletin 2023-09, Vol.49 (5), p.1161-1173 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1173 |
---|---|
container_issue | 5 |
container_start_page | 1161 |
container_title | Schizophrenia bulletin |
container_volume | 49 |
creator | Bershad, Anya K de Wit, Harriet |
description | Abstract
Background and Hypothesis
Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia.
Study Design
In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides.
Study Results
We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia.
Conclusions
Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered. |
doi_str_mv | 10.1093/schbul/sbad094 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/schbul/sbad094</oup_id><sourcerecordid>2829706135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</originalsourceid><addsrcrecordid>eNqFkUFP3DAQRi1UBFvolSPKsRwCHseOEy4IQVuQoCBBz9Zk4iWusnGwk5W2v560u6By4jTSzJs3I32MHQA_Bl5mJ5GaamxPYoU1L-UWm4GWKgXN4RObcVXkqc5B7rLPMf7mHGSZix22m-lMFYVQM0YPnhy2yX1cUeP7BsMCybf-aXWa_PRL2ybnfR88UmNjMvjkMVgckks7d-SGmLgu2Qhu_eCWODjf_WtS4_5MumA7h_tse45ttF82dY_9-v7t8eIqvbn7cX1xfpOSFGpIoZKVUiCxhFIhUjXPbSbqqqhqkrquIStUzvNaaxSYE_FCg7ZacC0ACHS2x87W3n6sFrYm2w0BW9MHt8CwMh6deT_pXGOe_NIAl0UmtZwMXzeG4J9HGwezcJFs22Jn_RiNKESpeQ6ZmtDjNUrBxxjs_O0OcPM3GrOOxmyimRYO___uDX_NYgKO1oAf-49kL_SxnQQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829706135</pqid></control><display><type>article</type><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bershad, Anya K ; de Wit, Harriet</creator><creatorcontrib>Bershad, Anya K ; de Wit, Harriet</creatorcontrib><description>Abstract
Background and Hypothesis
Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia.
Study Design
In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides.
Study Results
We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia.
Conclusions
Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</description><identifier>ISSN: 0586-7614</identifier><identifier>ISSN: 1745-1701</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/schbul/sbad094</identifier><identifier>PMID: 37358825</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Apathy ; Humans ; Motivation ; N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use ; Psychopharmacology ; Schizophrenia ; Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</subject><ispartof>Schizophrenia bulletin, 2023-09, Vol.49 (5), p.1161-1173</ispartof><rights>Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2023. 2023</rights><rights>Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2023.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</citedby><cites>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</cites><orcidid>0000-0002-3011-3730 ; 0000-0002-7211-8994</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483474/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483474/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,1579,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37358825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bershad, Anya K</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>Abstract
Background and Hypothesis
Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia.
Study Design
In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides.
Study Results
We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia.
Conclusions
Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</description><subject>Adult</subject><subject>Apathy</subject><subject>Humans</subject><subject>Motivation</subject><subject>N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use</subject><subject>Psychopharmacology</subject><subject>Schizophrenia</subject><subject>Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</subject><issn>0586-7614</issn><issn>1745-1701</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFP3DAQRi1UBFvolSPKsRwCHseOEy4IQVuQoCBBz9Zk4iWusnGwk5W2v560u6By4jTSzJs3I32MHQA_Bl5mJ5GaamxPYoU1L-UWm4GWKgXN4RObcVXkqc5B7rLPMf7mHGSZix22m-lMFYVQM0YPnhy2yX1cUeP7BsMCybf-aXWa_PRL2ybnfR88UmNjMvjkMVgckks7d-SGmLgu2Qhu_eCWODjf_WtS4_5MumA7h_tse45ttF82dY_9-v7t8eIqvbn7cX1xfpOSFGpIoZKVUiCxhFIhUjXPbSbqqqhqkrquIStUzvNaaxSYE_FCg7ZacC0ACHS2x87W3n6sFrYm2w0BW9MHt8CwMh6deT_pXGOe_NIAl0UmtZwMXzeG4J9HGwezcJFs22Jn_RiNKESpeQ6ZmtDjNUrBxxjs_O0OcPM3GrOOxmyimRYO___uDX_NYgKO1oAf-49kL_SxnQQ</recordid><startdate>20230907</startdate><enddate>20230907</enddate><creator>Bershad, Anya K</creator><creator>de Wit, Harriet</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3011-3730</orcidid><orcidid>https://orcid.org/0000-0002-7211-8994</orcidid></search><sort><creationdate>20230907</creationdate><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><author>Bershad, Anya K ; de Wit, Harriet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Apathy</topic><topic>Humans</topic><topic>Motivation</topic><topic>N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use</topic><topic>Psychopharmacology</topic><topic>Schizophrenia</topic><topic>Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bershad, Anya K</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bershad, Anya K</au><au>de Wit, Harriet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>2023-09-07</date><risdate>2023</risdate><volume>49</volume><issue>5</issue><spage>1161</spage><epage>1173</epage><pages>1161-1173</pages><issn>0586-7614</issn><issn>1745-1701</issn><eissn>1745-1701</eissn><abstract>Abstract
Background and Hypothesis
Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia.
Study Design
In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides.
Study Results
We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia.
Conclusions
Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37358825</pmid><doi>10.1093/schbul/sbad094</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3011-3730</orcidid><orcidid>https://orcid.org/0000-0002-7211-8994</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0586-7614 |
ispartof | Schizophrenia bulletin, 2023-09, Vol.49 (5), p.1161-1173 |
issn | 0586-7614 1745-1701 1745-1701 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483474 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central; Alma/SFX Local Collection |
subjects | Adult Apathy Humans Motivation N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use Psychopharmacology Schizophrenia Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia |
title | Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A19%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Social%20Psychopharmacology:%20Novel%20Approaches%20to%20Treat%20Deficits%20in%20Social%20Motivation%20in%20Schizophrenia&rft.jtitle=Schizophrenia%20bulletin&rft.au=Bershad,%20Anya%20K&rft.date=2023-09-07&rft.volume=49&rft.issue=5&rft.spage=1161&rft.epage=1173&rft.pages=1161-1173&rft.issn=0586-7614&rft.eissn=1745-1701&rft_id=info:doi/10.1093/schbul/sbad094&rft_dat=%3Cproquest_pubme%3E2829706135%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829706135&rft_id=info:pmid/37358825&rft_oup_id=10.1093/schbul/sbad094&rfr_iscdi=true |